当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2007年第29期
编号:11504770
长效钙通道阻滞剂的循证医学进展(2)
http://www.100md.com 2007年10月25日 《中国医药导报》 2007年第29期
     [6]Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin converting enzyme inhibitor in the antihypertensive and lipid lowering in the antihypertensive and lipid lowering treatment to prevent heart attack trial.(ALLHAT)[J].Hypertension,2006,48: 374-384.

    [7]Nissen SE.Effect of antihypertensive agents on cardiovascularevents in patients with coronary disease and normal blood pressure the Camelot study[J].JAMA,2004,292(18):2217-2225.

    [8]Fujikawa K,Hasebe N.Cost-effectiveness analysis of hypertension treatment:controlled release Nifedipine and candesartan lowdose combination therapy in patients with essential hypertension the Nifedipine and Candesartan Combination (NICE-Combi) study[J].Hypertension,2005,28 (7):585-591.

    [9]Poole-Wilson PA,Lubsen J,Kirwan BA,et al.A coronary disease trial investigating outcome with Nifedipine gastrointestinal therapeutic system investigators.Effect of long-acting Nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial):randomizedcontrolled trial[J].Lancet,2004,364(9437):849-857.

    [10]Lubsen J,Wagener G,Kirwan BA,et al.Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension.The Actlon trial[J].Hypertension,2005,23(3):641-648.

    [11]高润霖 .遵循指南规范慢性稳定性心绞痛诊断与治疗[J].中华心血管病杂志,2007,35(3):193-194.

    (收稿日期:2007-08-26), 百拇医药(陈 旸)
上一页1 2